Potent and Specific Antitumor Efficacy of CMC-544, a CD22-Targeted Immunoconjugate of Calicheamicin, against Systemically Disseminated B-Cell Lymphoma - Concepedia

Concepedia

Publication | Closed Access

Potent and Specific Antitumor Efficacy of CMC-544, a CD22-Targeted Immunoconjugate of Calicheamicin, against Systemically Disseminated B-Cell Lymphoma

99

Citations

36

References

2004

Year

John F. DiJoseph, Mary E.P. Goad, Maureen Dougher, Erwin R. Boghaert, Arthur Kunz, Philip R. Hamann, Nitin K. Damle

Clinical Cancer Research

Abstract

CMC-544 confers strong therapeutic activity against systemic disseminated B-cell lymphoma and protects mice from hind-limb paralysis and death. These results support clinical evaluation of CMC-544 in the treatment of CD22+ lymphoid malignancies.

References

	Year	Citations

Page 1